Chronic heart failure (CHF) is a serious complication of chemotherapy in cancer patients, including patients with gastric cancer (GC). With the increase in overall survival of such patients, the relevance of diagnosis and treatment of concomitant cardiovascular complications increases, which has led to the formation of a new discipline – cardiooncology. This survey research analyzes the mechanisms of pathogenesis, modern approaches to the prevention and treatment of CHF in the context of cardiotoxicity caused by chemotherapy for GC. An important role in the management of cardiac complications is played by timely diagnostics and a risk-adapted approach to the appointment of cardioprotectors, taking into account both standard risk factors for heart disease and the side effects of antitumor drugs. Therapeutic approaches to the treatment of type I and type II cardiotoxicity may differ; in the latter case, sometimes it is enough to discontinue the chemotherapeutic drug to restore cardiac function. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are usually considered as first-line drugs and/or in combination with β-blockers. In general, therapy for CHF in patients with gastric cancer should comply with the general principles of international clinical guidelines for cardiology and cardiooncology and be carried out in close cooperation between an oncologist and a cardiologist.

Keywords: chemotherapy, gastric cancer, cardiotoxicity, chronic heart failure